Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.

Vander Meeren S, Heyrman B, Renmans W, Bakkus M, Maes B, De Raeve H, Schots R, Jochmans K.

Ann Hematol. 2018 Jul;97(7):1219-1227. doi: 10.1007/s00277-018-3282-0. Epub 2018 Feb 28.

PMID:
29492600
2.

Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Žaliová M, Sutton R, Öfverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Froňková E, Bakkus M, Tchinda J, Barbosa TDC, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grümayer R, Kuiper RP, den Boer ML, Cavé H, Moorman AV, Harrison CJ, Strehl S.

Blood Adv. 2017 Aug 14;1(19):1473-1477. doi: 10.1182/bloodadvances.2017006734. eCollection 2017 Aug 22.

3.

Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.

Ghazavi F, De Moerloose B, Van Loocke W, Wallaert A, Helsmoortel HH, Ferster A, Bakkus M, Plat G, Delabesse E, Uyttebroeck A, Van Nieuwerburgh F, Deforce D, Van Roy N, Speleman F, Benoit Y, Lammens T, Van Vlierberghe P.

Oncotarget. 2016 Nov 8;7(45):73769-73780. doi: 10.18632/oncotarget.12063.

4.

A novel approach for BCR-ABL1 standardization to improve International Scale estimation.

Maes B, Bakkus M, Boeckx N, Boone E, Cauwelier B, Denys B, De Schouwer P, Devos T, El Housni H, Hillen F, Jacobs K, Lambert F, Louagie H, Maes MB, Meeus P, Moreau E, Nollet F, Peeters K, Saussoy P, Van Lint P, Vaerman JL, Vaeyens F, Vandepoele K, Vannuffel P, Ver Elst K, Vermeulen K, Bruyndonckx R; Belgian working group on BCR-ABL1 IS standardization.

Int J Lab Hematol. 2016 Dec;38(6):674-684. doi: 10.1111/ijlh.12556. Epub 2016 Jul 27.

PMID:
27460189
5.

CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.

Ghazavi F, Clappier E, Lammens T, Suciu S, Caye A, Zegrari S, Bakkus M, Grardel N, Benoit Y, Bertrand Y, Minckes O, Costa V, Ferster A, Mazingue F, Plat G, Plouvier E, Poirée M, Uyttebroeck A, van der Werff-Ten Bosch J, Yakouben K, Helsmoortel H, Meul M, Van Roy N, Philippé J, Speleman F, Cavé H, Van Vlierberghe P, De Moerloose B.

Haematologica. 2015 Oct;100(10):1311-9. doi: 10.3324/haematol.2015.126953. Epub 2015 Jul 2.

6.

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P, Caye A, Vivent J, Costa V, Ferster A, Lutz P, Mazingue F, Millot F, Plantaz D, Plat G, Plouvier E, Poirée M, Sirvent N, Uyttebroeck A, Yakouben K, Girard S, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Cavé H; European Organisation for Research and Treatment of Cancer, Children's Leukemia Group (EORTC-CLG).

Leukemia. 2015 Nov;29(11):2154-61. doi: 10.1038/leu.2015.134. Epub 2015 Jun 8.

PMID:
26050650
7.

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.

Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A, Giroux C, Hernandez L, Kabongo E, Savola S, Leblanc T, Yakouben K, Plat G, Costa V, Ferster A, Girard S, Fenneteau O, Cayuela JM, Sigaux F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Soulier J, Cavé H.

Leukemia. 2014 Jan;28(1):70-7. doi: 10.1038/leu.2013.277. Epub 2013 Sep 25.

PMID:
24064621
8.

Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results.

Dastugue N, Suciu S, Plat G, Speleman F, Cavé H, Girard S, Bakkus M, Pagès MP, Yakouben K, Nelken B, Uyttebroeck A, Gervais C, Lutz P, Teixeira MR, Heimann P, Ferster A, Rohrlich P, Collonge MA, Munzer M, Luquet I, Boutard P, Sirvent N, Karrasch M, Bertrand Y, Benoit Y.

Blood. 2013 Mar 28;121(13):2415-23. doi: 10.1182/blood-2012-06-437681. Epub 2013 Jan 15.

PMID:
23321258
9.

Reflections and proposals to assure quality in molecular diagnostics.

Raymaekers M, Bakkus M, Boone E, de Rijke B, El Housni H, Descheemaeker P, De Schouwer P, Franke S, Hillen F, Nollet F, Soetens O, Vankeerberghen A; MolecularDiagnostics.be working group.

Acta Clin Belg. 2011 Jan-Feb;66(1):33-41.

PMID:
21485761
10.

Guidelines for an integrated diagnostic approach of chronic lymphoproliferative disorders in the routine laboratory of haematology in Belgium.

Philippé J, Nollet F, Bakkus M, Meeus P, Demanet C, Schaaf-Lafontaine N, Franke S, Chatelain B, Vermeulen K, Boone E, El Housni H, Heimann P, Husson B, Lambert F, Vannuffel P, Saussoy P, Maes B, Deschouwer P.

Acta Clin Belg. 2009 Nov-Dec;64(6):494-504.

PMID:
20101872
11.

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.

Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, Salles G, Feremans W, Apperley J, Samson D, Björkstrand B, Niederwieser D, Gahrton G, Pico JL, Goldschmidt H; European Group for Blood and Marrow Transplantation.

Haematologica. 2007 Aug;92(8):1083-90. Epub 2007 Jul 20.

12.

Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3.

De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, Van Riet I.

Haematologica. 2007 Apr;92(4):440-9.

13.

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.

Bakkus MH, Bouko Y, Samson D, Apperley JF, Thielemans K, Van Camp B, Benner A, Goldschmidt H, Moos M, Cremer FW.

Br J Haematol. 2004 Sep;126(5):665-74.

PMID:
15327517
14.

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, Vanderkerken K.

Br J Cancer. 2004 Mar 8;90(5):1076-83.

15.

Myeloma clonotypic B cells are hampered in their ability to undergo B-cell differentiation in vitro.

Guikema JE, Vellenga E, Bakkus MH, Bos NA.

Br J Haematol. 2002 Oct;119(1):54-61.

PMID:
12358903
16.

Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells.

Van Valckenborgh E, Bakkus M, Munaut C, Noël A, St Pierre Y, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K.

Int J Cancer. 2002 Oct 20;101(6):512-8.

17.

Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour.

Bakkus MH, Asosingh K, Vanderkerken K, Thielemans K, Hagemeijer A, De Raeve H, Van Camp B.

Leukemia. 2001 Jul;15(7):1127-32.

18.

CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13.

Bullens DM, Kasran A, Thielemans K, Bakkus M, Ceuppens JL.

Scand J Immunol. 2001 May;53(5):455-63.

19.

Clonally related IgA- and IgE-secreting plasma cells in a myeloma patient.

Bakkus MH, Schots R, Gomez La Fuente PB, Van Riet I, Thielemans K, De Waele M, Van Camp B.

Eur J Haematol. 2000 Nov;65(5):348-55.

PMID:
11092467
20.

Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus.

Gancberg D, Zeicher M, Bakkus M, Dupont F, Leo O, Moser M, Spegelaere P, Thielemans K, Urbain J, Horth M.

Anticancer Res. 2000 May-Jun;20(3A):1825-32.

PMID:
10928114
21.

In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells.

Asosingh K, Günthert U, Bakkus MH, De Raeve H, Goes E, Van Riet I, Van Camp B, Vanderkerken K.

Cancer Res. 2000 Jun 1;60(11):3096-104.

22.

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

Jacquemin M, Benhida A, Peerlinck K, Desqueper B, Vander Elst L, Lavend'homme R, d'Oiron R, Schwaab R, Bakkus M, Thielemans K, Gilles JG, Vermylen J, Saint-Remy JM.

Blood. 2000 Jan 1;95(1):156-63.

PMID:
10607698
23.

The genetic variability of the VH genes in follicular lymphoma: the impact of the hypermutation mechanism.

Noppe SM, Heirman C, Bakkus MH, Brissinck J, Schots R, Thielemans K.

Br J Haematol. 1999 Dec;107(3):625-40.

PMID:
10583269
24.

Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) DNA sequences are absent in leukapheresis products and ex vivo expanded CD34+ cells from multiple myeloma patients.

De Greef C, Van De Voorde W, Bakkus M, Corthals J, Heirman C, Schots R, Lacor P, Van Camp B, Van Riet I.

Br J Haematol. 1999 Sep;106(4):1033-6.

PMID:
10520008
25.

Genes encoding tumor-specific antigens are expressed in human myeloma cells.

van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, André M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, Boon T.

Blood. 1999 Aug 15;94(4):1156-64.

PMID:
10438702
26.

Use of quantitative ASO-PCR to predict relapse in multiple myeloma.

Cooke F, Bakkus M, Thielemans K, Pico JL, Apperley JF, Samson D.

Br J Haematol. 1999 Apr;105(1):317-9. No abstract available.

PMID:
10366251
27.

Ig gene sequences in the study of clonality.

Bakkus MH.

Pathol Biol (Paris). 1999 Feb;47(2):128-47. Review.

PMID:
10192880
28.

Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation.

Guikema JE, Vellenga E, Veeneman JM, Hovenga S, Bakkus MH, Klip H, Bos NA.

Br J Haematol. 1999 Mar;104(4):748-54.

PMID:
10192436
29.

Immunoglobulins D and M multiple myeloma variants are heavily mutated.

Juge-Morineau N, Heirman C, Bakkus M, Van Camp B, Malfait R, Harousseau JL, Thielemans K, Bataille R.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2501-6.

30.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E.

N Engl J Med. 1998 Aug 27;339(9):591-8.

31.

The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency.

van der Werff ten Bosch JE, Demanet C, Balduck N, Bakkus MH, De Raeve H, Desprechins B, Otten J, Thielemans K.

Br J Haematol. 1998 Jul;102(2):578-81.

PMID:
9695976
32.

Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.

Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JG, Vermylen J, Saint-Remy JM.

Blood. 1998 Jul 15;92(2):496-506.

PMID:
9657749
33.
34.

ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia.

Cavé H, Cacheux V, Raynaud S, Brunie G, Bakkus M, Cochaux P, Preudhomme C, Laï JL, Vilmer E, Grandchamp B.

Leukemia. 1997 Sep;11(9):1459-64.

35.
36.

Persistence of residual tumour cells after cytokine-mediated ex vivo expansion of mobilized CD34+ blood cells in multiple myeloma.

Van Riet I, Juge-Morineau N, Schots R, De Waele M, De Greef C, Thielemans K, Van Camp B, Bakkus M.

Br J Haematol. 1997 Feb;96(2):403-11.

PMID:
9029033
37.

Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2).

Van Riet I, De Greef C, Aharchi F, Woischwill C, De Waele M, Bakkus M, Lacor P, Schots R, Van Camp B.

Leukemia. 1997 Feb;11(2):284-93.

38.

Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen.

Planken EV, Dijkstra NH, Bakkus M, Willemze R, Kluin-Nelemans JC.

Br J Haematol. 1996 Nov;95(2):319-26.

PMID:
8904887
39.

Detection of minimal residual disease in multiple myeloma and acute leukaemia.

Bakkus MH, Juge-Morineau N, van der Werff ten Bosch JE.

Med Oncol. 1996 Jun;13(2):121-31. Review.

PMID:
9013476
40.

Homing mechanisms in the etiopathogenesis of multiple myeloma.

Van Riet I, Bakkus M, De Greef C, Faid L, Van Camp B.

Stem Cells. 1995 Aug;13 Suppl 2:22-7. Review.

PMID:
8520507
41.

The clonogenic precursor cell in multiple myeloma.

Bakkus MH, Van Riet I, De Greef C, Van Camp B, Thielemans K.

Leuk Lymphoma. 1995 Jul;18(3-4):221-9. Review.

PMID:
8535186
42.

Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity.

Geldhof AB, Raes G, Bakkus M, Devos S, Thielemans K, De Baetselier P.

Cancer Res. 1995 Jul 1;55(13):2730-3.

43.

Co-stimulation lowers the threshold for activation of naive T cells by bacterial superantigens.

Muraille EM, De Becker G, Bakkus M, Thielemans K, Urbain J, Moser M, Leo O.

Int Immunol. 1995 Feb;7(2):295-304.

PMID:
7734424
44.

Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens.

VandenDriessche T, Geldhof A, Bakkus M, Toussaint-Demylle D, Brijs L, Thielemans K, Verschueren H, De Baetselier P.

Int J Cancer. 1994 Jul 15;58(2):217-25.

PMID:
8026885
45.

Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell.

Bakkus MH, Van Riet I, Van Camp B, Thielemans K.

Br J Haematol. 1994 May;87(1):68-74.

PMID:
7947257
46.

Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.

Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M.

Eur J Immunol. 1994 Mar;24(3):605-10.

PMID:
8125131
47.

Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens.

VandenDriessche T, Bakkus M, Toussaint-Demylle D, Thielemans K, Verschueren H, De Baetselier P.

Clin Exp Metastasis. 1994 Jan;12(1):73-83.

PMID:
8287623
48.

CD45RO+ memory T cells but not CD45RA+ naive T cells can be efficiently activated by remote co-stimulation with B7.

Van de Velde H, Lorré K, Bakkus M, Thielemans K, Ceuppens JL, de Boer M.

Int Immunol. 1993 Nov;5(11):1483-7.

PMID:
7505109
49.

Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.

Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K.

Blood. 1992 Nov 1;80(9):2326-35.

PMID:
1421403
50.

Detection of Interleukin-1β and Interleukin-6 in Human Multiple Myeloma by Fluorescent in situ Hybridization.

Bakkus MH, Brakel-Van Peer KM, Adriaansen HJ, Van Den Akker TW, Benner R.

Leuk Lymphoma. 1991;4(5-6):389-95. doi: 10.3109/10428199109068091.

PMID:
27467673

Supplemental Content

Loading ...
Support Center